HDL in infectious diseases and sepsis

Handbook of Experimental Pharmacology

Volumn 224, Issue , 2015, Pages 483-508

  Pirillo, Angela ^a,b   Catapano, Alberico Luigi ^a,b   Norata, Giuseppe Danilo ^a,c  

^a Bassini Hospital   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Bacteria; HDL; Infections; Parasites; Virus

Indexed keywords

ABC TRANSPORTER A1; ACTIVATING TRANSCRIPTION FACTOR 3; APOLIPOPROTEIN A1; APOLIPOPROTEIN M; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1Q; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; PENTRAXIN 3; SCAVENGER RECEPTOR BI; SECRETORY PHOSPHOLIPASE A2; SERUM AMYLOID A; SPHINGOSINE 1 PHOSPHATE; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ANTIGEN PRESENTATION; ANTIOXIDANT ACTIVITY; B LYMPHOCYTE; BACTERIAL INFECTION; BIOAVAILABILITY; CATALYSIS; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DENDRITIC CELL; DISEASE ASSOCIATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LIPID METABOLISM; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MYCOBACTERIUM; NONHUMAN; PARASITOSIS; PHAGOCYTE; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SEPSIS; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS ENTRY; VIRUS INFECTION; ANIMAL; BLOOD; HOST PARASITE INTERACTION; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PARASITOLOGY; VIROLOGY;

ANIMALS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; HOST-PARASITE INTERACTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; LIPOPROTEINS, HDL; PARASITIC DISEASES; SEPSIS; VIRUS DISEASES;

EID: 84919665057     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-319-09665-0_15     Document Type: Conference Paper

References (138)

1. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX (1999) Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 96:12766-12771
2. Badellino KO, Wolfe ML, Reilly MP, Rader DJ (2008) Endothelial lipase is increased in vivo by inflammation in humans. Circulation 117:678-685. doi:10.1161/CIRCULATIONAHA.107.707349
3. Baker JV, Neuhaus J, Duprez D, Cooper DA, Hoy J, Kuller L, Lampe FC, Liappis A, Friis- Moller N, Otvos J, Paton NI, Tracy R, Neaton JD, Group ISS (2011) Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS 25:2133-2142. doi:10.1097/QAD.0b013e32834be088
4. Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC (1995) Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 36:1058-1065
5. Baragetti A, Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, Uboldi P, Baragetti I, Pozzi C, Catapano AL (2013) High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med 274:252-262. doi:10.1111/ joim.12081
6. Baral TN, Magez S, Stijlemans B, Conrath K, Vanhollebeke B, Pays E, Muyldermans S, De Baetselier P (2006) Experimental therapy of African trypanosomiasis with a nanobodyconjugated human trypanolytic factor. Nat Med 12:580-584. doi:10.1038/nm1395
7. Barlage S, Frohlich D, Bottcher A, Jauhiainen M, Muller HP, Noetzel F, Rothe G, Schutt C, Linke RP, Lackner KJ, Ehnholm C, Schmitz G (2001) ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 42:281-290
8. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122. doi:10.1056/NEJMoa0706628
9. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL (2003) Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278:41624-41630. doi:10.1074/jbc.M305289200
10. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL (2005) An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79:8217-8229. doi:10.1128/JVI.79.13.8217-8229.2005
11. Baruah P, Dumitriu IE, Peri G, Russo V, Mantovani A, Manfredi AA, Rovere-Querini P (2006) The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol 80:87-95. doi:10.1189/jlb.0805445
12. Berbee JF, van der Hoogt CC, Kleemann R, Schippers EF, Kitchens RL, van Dissel JT, Bakker- Woudenberg IA, Havekes LM, Rensen PC (2006) Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis. Faseb J 20:2162-2164
13. Bhakdi S, Klonisch T, Nuber P, Fischer W (1991) Stimulation of monokine production by lipoteichoic acids. Infect Immun 59:4614-4620
14. Birjmohun RS, van Leuven SI, Levels JH, van’t Veer C, Kuivenhoven JA, Meijers JC, Levi M, Kastelein JJ, van der Poll T, Stroes ES (2007) High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 27:1153-1158. doi:10.1161/ATVBAHA.106.136325
15. Bonacina F, Baragetti A, Catapano AL, Norata GD (2013) Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. Mediators Inflamm 2013:725102. doi:10.1155/2013/725102
16. Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, Spreafico F, Pausa M, D’Ettorre C, Gianazza E, Tagliabue A, Salmona M, Tedesco F, Introna M, Mantovani A (1997) Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 272:32817-32823
17. Bozza S, Bistoni F, Gaziano R, Pitzurra L, Zelante T, Bonifazi P, Perruccio K, Bellocchio S, Neri M, Iorio AM, Salvatori G, De Santis R, Calvitti M, Doni A, Garlanda C, Mantovani A, Romani L (2006) Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood 108:3387-3396. doi:10.1182/blood-2006-03-009266
18. Breviario F, d’Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M et al (1992) Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 267:22190-22197
19. Cao Y, Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM (1998) Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem 273:4012-4020
20. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A (2007) High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 81:8063-8071. doi:10.1128/JVI.00193-07
21. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A (2010) Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 84:34-43. doi:10.1128/JVI.02199-08
22. Chien JY, Jerng JS, Yu CJ, Yang PC (2005) Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 33:1688-1693
23. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, Egerer- Sieber C, Muller YA, Hla T, Nielsen LB, Dahlback B (2011) Endothelium-protective sphingosine- 1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 108:9613-9618. doi:10.1073/pnas.1103187108
24. Clark RW, Cunningham D, Cong Y, Subashi TA, Tkalcevic GT, Lloyd DB, Boyd JG, Chrunyk BA, Karam GA, Qiu X, Wang IK, Francone OL (2010) Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection. J Lipid Res 51:967-974. doi:10.1194/jlr.M002295
25. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC (1986) Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 261:9644-9651
26. Cruz D, Watson AD, Miller CS, Montoya D, Ochoa MT, Sieling PA, Gutierrez MA, Navab M, Reddy ST, Witztum JL, Fogelman AM, Rea TH, Eisenberg D, Berliner J, Modlin RL (2008) Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest 118:2917-2928. doi:10.1172/JCI34189
27. Dai L, Datta G, Zhang Z, Gupta H, Patel R, Honavar J, Modi S, Wyss JM, Palgunachari M, Anantharamaiah GM, White CR (2010) The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J Lipid Res 51:2695-2705. doi:10.1194/jlr.M008086
28. Dao Thi VL, Granier C, Zeisel MB, Guerin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M (2012) Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem 287:31242-31257. doi:10.1074/jbc.M112.365924
29. Datta G, Gupta H, Zhang Z, Mayakonda P, Anantharamaiah GM, White CR (2011) HDL mimetic peptide administration improves left ventricular filling and cardiac output in lipopolysaccharide-treated rats. J Clin Exp Cardiolog 2:pii: 1000172. doi:10.4172/2155-9880.1000172
30. De Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR (1995) The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci USA 92:10359-10363
31. de la Llera MM, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, Tabita-Martinez J, Wolfe ML, Badellino K, Pruscino L, Mehta NN, Asztalos BF, Reilly MP (2012) Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 222:390-394. doi:10.1016/j.atherosclerosis.2012.02.032/S0021-9150(12)00146-3
32. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, Riesen W, Nicod P, Darioli R, Telenti A, Mooser V, Swiss HIVCS (2001) Premature atherosclerosis in HIV-infected individuals - focus on protease inhibitor therapy. AIDS 15:329-334
33. Diniz SN, Nomizo R, Cisalpino PS, Teixeira MM, Brown GD, Mantovani A, Gordon S, Reis LF, Dias AA (2004) PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages. J Leukoc Biol 75:649-656. doi:10.1189/jlb.0803371
34. Doni A, Mantovani G, Porta C, Tuckermann J, Reichardt HM, Kleiman A, Sironi M, Rubino L, Pasqualini F, Nebuloni M, Signorini S, Peri G, Sica A, Beck-Peccoz P, Bottazzi B, Mantovani A (2008) Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and nonhematopoietic cells. J Biol Chem 283:29983-29992. doi:10.1074/jbc.M805631200
35. Doni A, Garlanda C, Bottazzi B, Meri S, Garred P, Mantovani A (2012) Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology 217:1122-1128. doi:10.1016/j.imbio.2012.07.004/S0171-2985(12)00168-4
36. Dreux M, Dao Thi VL, Fresquet J, Guerin M, Julia Z, Verney G, Durantel D, Zoulim F, Lavillette D, Cosset FL, Bartosch B (2009) Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog 5:e1000310. doi:10.1371/journal.ppat.1000310
37. Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O’Connor PM, Malloy MJ, Kane JP (1997) Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem 272:25576-25582
38. Emancipator K, Csako G, Elin RJ (1992) In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 60:596-601
39. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805. doi:10.1038/nature05654
40. Eyre NS, Drummer HE, Beard MR (2010) The SR-BI partner PDZK1 facilitates hepatitis C virus entry. PLoS Pathog 6:e1001130. doi:10.1371/journal.ppat.1001130
41. Feingold KR, Memon RA, Moser AH, Grunfeld C (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139:307-315
42. Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovidhunkit W, Grunfeld C (2008) Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 199:19-26. doi:10.1016/j.atherosclerosis.2007.10.007/S0021-9150(07)00660-0
43. Fitzgerald ML, Mujawar Z, Tamehiro N (2010) ABC transporters, atherosclerosis and inflammation. Atherosclerosis 211:361-370. doi:10.1016/j.atherosclerosis.2010.01.011
44. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H (1993) Prevention of endotoxininduced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 61:5140-5146
45. Franssen R, Sankatsing RR, Hassink E, Hutten B, Ackermans MT, Brinkman K, Oesterholt R, Arenas-Pinto A, Storfer SP, Kastelein JJ, Sauerwein HP, Reiss P, Stroes ES (2009) Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol 29:1336-1341. doi:10.1161/ATVBAHA.109.192088
46. Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, Maccagno A, Riva F, Bottazzi B, Peri G, Doni A, Vago L, Botto M, De Santis R, Carminati P, Siracusa G, Altruda F, Vecchi A, Romani L, Mantovani A (2002) Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420:182-186
47. Garlanda C, Bottazzi B, Bastone A, Mantovani A (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23:337-366
48. Gershov D, Kim S, Brot N, Elkon KB (2000) C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192:1353-1364
49. Grunfeld C, Marshall M, Shigenaga JK, Moser AH, Tobias P, Feingold KR (1999) Lipoproteins inhibit macrophage activation by lipoteichoic acid. J Lipid Res 40:245-252
50. Guo L, Ai J, Zheng Z, Howatt DA, Daugherty A, Huang B, Li XA (2013) High density lipoprotein protects against polymicrobe-induced sepsis in mice. J Biol Chem 288:17947-17953. doi:10.1074/jbc.M112.442699
51. Gupta H, Dai L, Datta G, Garber DW, Grenett H, Li Y, Mishra V, Palgunachari MN, Handattu S, Gianturco SH, Bradley WA, Anantharamaiah GM, White CR (2005) Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 97:236-243
52. Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, Cosset FL, Koutsoudakis G, Bartenschlager R, Union A, Depla E, Owsianka A, Patel AH, Schuster C, Stoll-Keller F, Doffoel M, Dreux M, Baumert TF (2008) Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 135(1719-1728):e1. doi:10.1053/j.gastro.2008.07.018
53. Harris HJ, Farquhar MJ, Mee CJ, Davis C, Reynolds GM, Jennings A, Hu K, Yuan F, Deng H, Hubscher SG, Han JH, Balfe P, McKeating JA (2008) CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 82:5007-5020. doi:10.1128/JVI.02286-07
54. Henning MF, Herlax V, Bakas L (2011) Contribution of the C-terminal end of apolipoprotein AI to neutralization of lipopolysaccharide endotoxic effect. Innate Immun 17:327-337
55. Hijikata M, Shimizu YK, Kato H, Iwamoto A, Shih JW, Alter HJ, Purcell RH, Yoshikura H (1993) Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 67:1953-1958
56. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, Naoumova R, Thompson GR, Seed M, Durrington PN, Miller JP, Betteridge DJ, Neil HA (2006) Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 43:943-949
57. Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity by the innate immune system. Science 327:291-295. doi:10.1126/science.1183021/327/5963/291
58. Jaillon S, Jeannin P, Hamon Y, Fremaux I, Doni A, Bottazzi B, Blanchard S, Subra JF, Chevailler A, Mantovani A, Delneste Y (2009) Endogenous PTX3 translocates at the membrane of late apoptotic human neutrophils and is involved in their engulfment by macrophages. Cell Death Differ 16:465-474. doi:10.1038/cdd.2008.173
59. Jeannin P, Bottazzi B, Sironi M, Doni A, Rusnati M, Presta M, Maina V, Magistrelli G, Haeuw JF, Hoeffel G, Thieblemont N, Corvaia N, Garlanda C, Delneste Y, Mantovani A (2005) Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity 22:551-560. doi:10.1016/j.immuni.2005.03.008/S1074-7613(05)00103-2
60. Jerala R (2007) Structural biology of the LPS recognition. Int J Med Microbiol 297:353-363. doi:10.1016/j.ijmm.2007.04.001/S1438-4221(07)00068-9
61. Jiao YL, Wu MP (2008) Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 43:83-87. doi:10.1016/j.cyto.2008.04.002/S1043-4666(08)00099-9
62. Kelesidis T, Yang OO, Currier JS, Navab K, Fogelman AM, Navab M (2011) HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids Health Dis 10:35. doi:10.1186/1476-511X-10-35
63. Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS (2013) Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults. Lipids Health Dis 12:23. doi:10.1186/1476-511X-12-23
64. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45:1169-1196
65. Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58:342-374
66. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C, Baumert TF (2010) Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51:1144-1157. doi:10.1002/hep.23445
67. Kumaraswamy SB, Linder A, Akesson P, Dahlback B (2012) Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes. Crit Care 16:R60. doi:10.1186/cc11305/cc11305
68. Kwon WY, Suh GJ, Kim KS, Kwak YH, Kim K (2012) 4F, apolipoprotein AI mimetic peptide, attenuates acute lung injury and improves survival in endotoxemic rats. J Trauma Acute Care Surg 72:1576-1583. doi:10.1097/TA.0b013e3182493ab4/01586154-201206000-00023
69. Lavie M, Voisset C, Vu-Dac N, Zurawski V, Duverlie G, Wychowski C, Dubuisson J (2006) Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology 44:1626-1634. doi:10.1002/hep.21406
70. Lee GW, Lee TH, Vilcek J (1993) TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 150:1804-1812
71. Lee RP, Lin NT, Chao YF, Lin CC, Harn HJ, Chen HI (2007) High-density lipoprotein prevents organ damage in endotoxemia. Res Nurs Health 30:250-260. doi:10.1002/nur.20187
72. Levels JH, Abraham PR, van Barreveld EP, Meijers JC, van Deventer SJ (2003) Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect Immun 71:3280-3284
73. Levels JH, Geurts P, Karlsson H, Maree R, Ljunggren S, Fornander L, Wehenkel L, Lindahl M, Stroes ES, Kuivenhoven JA, Meijers JC (2011) High-density lipoprotein proteome dynamics in human endotoxemia. Proteome Sci 9:34. doi:10.1186/1477-5956-9-34
74. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL (1993) In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 90:12040-12044
75. Li Y, Dong JB, Wu MP (2008) Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. Eur J Pharmacol 590:417-422. doi:10.1016/ j.ejphar.2008.06.047/S0014-2999(08)00656-0
76. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17:589-595. doi:10.1038/nm.2341
77. Madamanchi NR, Patterson C, Runge MS (2002) HIV therapies and atherosclerosis: answers or questions? Arterioscler Thromb Vasc Biol 22:1758-1760
78. Maillard P, Huby T, Andreo U, Moreau M, Chapman J, Budkowska A (2006) The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoBcontaining lipoproteins. FASEB J 20:735-737. doi:10.1096/fj.05-4728fje
79. Mancone C, Steindler C, Santangelo L, Simonte G, Vlassi C, Longo MA, D’Offizi G, Di Giacomo C, Pucillo LP, Amicone L, Tripodi M, Alonzi T (2011) Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent lowdensity lipoproteins. Gut 60:378-386. doi:10.1136/gut.2010.211292
80. McGillicuddy FC, de la Llera MM, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP (2009) Inflammation impairs reverse cholesterol transport in vivo. Circulation 119:1135-1145
81. Memon RA, Fuller J, Moser AH, Feingold KR, Grunfeld C (1999) In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am J Physiol 277: R94-R103
82. Meuleman P, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, Sheahan T, Grzyb K, Cortese R, Rice CM, Leroux-Roels G, Nicosia A (2012) A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 55:364-372. doi:10.1002/hep.24692
83. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, Fu Y, Dart A, Orenstein JM, Bobryshev YV, Bukrinsky M, Sviridov D (2006) Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 4:e365. doi:10.1371/journal.pbio.0040365
84. Mujawar Z, Tamehiro N, Grant A, Sviridov D, Bukrinsky M, Fitzgerald ML (2010) Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation. Biochemistry 49:8338-8349. doi:10.1021/bi100466q
85. Murch O, Collin M, Hinds CJ, Thiemermann C (2007) Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 33:13-24
86. Murphy AJ, Woollard KJ, Suhartoyo A, Stirzaker RA, Shaw J, Sviridov D, Chin-Dusting JP (2011) Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein a-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol 31:1333-1341
87. Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ, Gingras AR, Tzima S, Vivanco F, Egido J, Tijsma O, Hack EC, Daha MR, Roos A (2003) Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 33:465-473. doi:10.1002/immu.200310022
88. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM (2004) The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45:993-1007
89. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL (2006) Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 80:2418-2428. doi:10.1128/JVI.80.5.2418-2428.2006
90. Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano AL (2005) High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 111:2805-2811
91. Norata GD, Pirillo A, Catapano AL (2006) Modified HDL: biological and physiopathological consequences. Nutr Metab Cardiovasc Dis 16(5):371-386
92. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, Garlanda C, Mantovani A, Catapano AL (2008) Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 28:925-931. doi:10.1161/ATVBAHA.107.160606
93. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL (2009) Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120:699-708. doi:10.1161/CIRCULATIONAHA.108.806547
94. Norata GD, Garlanda C, Catapano AL (2010) The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 20:35-40. doi:10.1016/j.tcm.2010.03.005/S1050-1738(10)00036-8
95. Norata GD, Pirillo A, Catapano AL (2011) HDLs, immunity, and atherosclerosis. Curr Opin Lipidol 22:410-416. doi:10.1097/MOL.0b013e32834adac3
96. Norata GD, Pirillo A, Ammirati E, Catapano AL (2012) Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 220:11-21. doi:10.1016/j.atherosclerosis.2011.06.045
97. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJ (1996) Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 184:1601-1608
98. Parker TS, Levine DM, Chang JC, Laxer J, Coffin CC, Rubin AL (1995) Reconstituted highdensity lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 63:253-258
99. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ, AASK Study Investigators, CRIC Study Investigators (2013) APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369(23):2183-2196. doi:10.1056/NEJMoa1310345
100. Pereira SA, Batuca JR, Caixas U, Branco T, Delgado-Alves J, Germano I, Lampreia F, Monteiro EC (2009) Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients. Br J Clin Pharmacol 68:891-897. doi:10.1111/j.1365-2125.2009.03535.x
101. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homble F, Vanhamme L, Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E (2005) Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 309:469-472. doi:10.1126/science.1114566
102. Pirillo A, Norata GD, Catapano AL (2013) Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality. Curr Pharm Des 19:3841-3857
103. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886. doi:10.1038/nature07684
104. Poon IK, Hulett MD, Parish CR (2010) Molecular mechanisms of late apoptotic/necrotic cell clearance. Cell Death Differ 17:381-397. doi:10.1038/cdd.2009.195
105. Reading PC, Bozza S, Gilbertson B, Tate M, Moretti S, Job ER, Crouch EC, Brooks AG, Brown LE, Bottazzi B, Romani L, Mantovani A (2008) Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J Immunol 180:3391-3398
106. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA (2003) Impact of HIV infection and HAART on serum lipids in men. JAMA 289:2978-2982. doi:10.1001/jama.289.22.2978
107. Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, Sviridov D (2006) HIV infection and highdensity lipoprotein: the effect of the disease vs the effect of treatment. Metabolism 55:90-95. doi:10.1016/j.metabol.2005.07.012
108. Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, Sviridov D (2008) HIV infection and high density lipoprotein metabolism. Atherosclerosis 199:79-86. doi:10.1016/j.atherosclerosis.2007.10.018
109. Roumenina LT, Ruseva MM, Zlatarova A, Ghai R, Kolev M, Olova N, Gadjeva M, Agrawal A, Bottazzi B, Mantovani A, Reid KB, Kishore U, Kojouharova MS (2006) Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry 45:4093-4104. doi:10.1021/bi052646f
110. Rovere P, Peri G, Fazzini F, Bottazzi B, Doni A, Bondanza A, Zimmermann VS, Garlanda C, Fascio U, Sabbadini MG, Rugarli C, Mantovani A, Manfredi AA (2000) The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 96:4300-4306
111. Sala F, Catapano AL, Norata GD (2012) High density lipoproteins and atherosclerosis: emerging aspects. J Geriatr Cardiol 9:401-407. doi:10.3724/SP.J.1263.2011.12282
112. Sala F, Cutuli L, Grigore L, Pirillo A, Chiesa G, Catapano AL, Norata GD (2013) Prevalence of classical CD14++/CD16_ but not of intermediate CD14++/CD16+ monocytes in hypoalphalipoproteinemia. Int J Cardiol 168:2886-2889. doi:10.1016/j.ijcard.2013.03.103
113. Samanovic M, Molina-Portela MP, Chessler AD, Burleigh BA, Raper J (2009) Trypanosome lytic factor, an antimicrobial high-density lipoprotein, ameliorates Leishmania infection. PLoS Pathog 5:e1000276. doi:10.1371/journal.ppat.1000276
114. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21:5017-5025
115. Sherman CB, Peterson SJ, Frishman WH (2010) Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev 18:141-147. doi:10.1097/CRD.0b013e3181c4b508
116. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, Mantero-Atienza E, Baum MK (1993) Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 94:515-519
117. Srinivas RV, Birkedal B, Owens RJ, Anantharamaiah GM, Segrest JP, Compans RW (1990) Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs. Virology 176:48-57
118. Suzuki M, Pritchard DK, Becker L, Hoofnagle AN, Tanimura N, Bammler TK, Beyer RP, Bumgarner R, Vaisar T, de Beer MC, de Beer FC, Miyake K, Oram JF, Heinecke JW (2010) High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation 122:1919-1927
119. Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA, McKelvy J, Wong-Staal F (2011) Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 54:48-55. doi:10.1016/j.jhep.2010.06.024
120. Thompson PA, Kitchens RL (2006) Native high-density lipoprotein augments monocyte responses to lipopolysaccharide (LPS) by suppressing the inhibitory activity of LPS-binding protein. J Immunol 177:4880-4887. doi:10.4049/jimmunol.177.7.4880
121. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A (1992) Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol 181:293-300
122. Tobias PS, Soldau K, Ulevitch RJ (1989) Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 264:10867-10871
123. Ulevitch RJ, Johnston AR, Weinstein DB (1979) New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest 64:1516- 1524. doi:10.1172/JCI109610
124. Ulevitch RJ, Johnston AR, Weinstein DB (1981) New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma. J Clin Invest 67:827-837. doi:10.1172/JCI110100
125. Van Amersfoort ES, Van Berkel TJ, Kuiper J (2003) Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 16:379-414
126. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP (2003) Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 31:1359-1366
127. van Rossum AP, Fazzini F, Limburg PC, Manfredi AA, Rovere-Querini P, Mantovani A, Kallenberg CG (2004) The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthritis Rheum 50:2667-2674. doi:10.1002/art.20370
128. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, Pays A, Tebabi P, Van Xong H, Jacquet A, Moguilevsky N, Dieu M, Kane JP, De Baetselier P, Brasseur R, Pays E (2003) Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 422:83-87. doi:10.1038/nature01461
129. Vishnyakova TG, Bocharov AV, Baranova IN, Chen Z, Remaley AT, Csako G, Eggerman TL, Patterson AP (2003) Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J Biol Chem 278:22771-22780. doi:10.1074/jbc.M211032200
130. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N (2005) High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 280:7793-7799. doi:10.1074/jbc.M411600200
131. von Hahn T, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, Rice CM, McKeating JA (2006) Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 43:932-942. doi:10.1002/hep.21139
132. Wendel M, Paul R, Heller AR (2007) Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 33:25-35. doi:10.1007/s00134-006-0433-x
133. Wheeler RJ (2010) The trypanolytic factormechanism, impacts and applications. Trends Parasitol 26:457-464. doi:10.1016/j.pt.2010.05.005
134. White CR, Datta G, Mochon P, Zhang Z, Kelly O, Curcio C, Parks D, Palgunachari M, Handattu S, Gupta H, Garber DW, Anantharamaiah GM (2009) Vasculoprotective effects of apolipoprotein mimetic peptides: an evolving paradigm in HDL therapy. Vasc Dis Prev 6:122-130. doi:10.2174/1567270000906010122
135. Wolfrum C, Poy MN, Stoffel M (2005) Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 11:418-422. doi:10.1038/nm1211
136. Zahid MN, Turek M, Xiao F, Thi VL, Guerin M, Fofana I, Bachellier P, Thompson J, Delang L, Neyts J, Bankwitz D, Pietschmann T, Dreux M, Cosset FL, Grunert F, Baumert TF, Zeisel MB (2013) The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 57:492-504. doi:10.1002/hep.26097
137. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, Wakita T, Jaeck D, Doffoel M, Royer C, Soulier E, Schvoerer E, Schuster C, Stoll-Keller F, Bartenschlager R, Pietschmann T, Barth H, Baumert TF (2007) Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46:1722-1731. doi:10.1002/hep.21994
138. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF (2011) Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 54:566-576. doi:10.1016/j.jhep.2010.10.014